{"id":"NCT00411645","sponsor":"Shire","briefTitle":"Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-13","primaryCompletion":"2008-11-10","completion":"2009-05-23","firstPosted":"2006-12-14","resultsPosted":"2015-06-03","lastUpdate":"2021-06-11"},"enrollment":681,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infections"],"interventions":[{"type":"DRUG","name":"maribavir","otherNames":[]},{"type":"OTHER","name":"placebo","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.","primaryOutcome":{"measure":"Number of Participants With Endpoint Committee (EC)-Confirmed Cytomegalovirus (CMV) Disease Within 6 Months Post-Transplantation","timeFrame":"6 months post-transplant","effectByArm":[{"arm":"Placebo","deltaMin":11,"sd":null},{"arm":"Maribavir 100 mg BID","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.789"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":97,"countries":["United States","Belgium","Canada","France","Germany","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["21414843"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":98,"n":223},"commonTop":["Acute Graft Versus Host Disease","Diarrhoea","Nausea","Fatigue","Rash"]}}